0.5311
5.77%
-0.0325
Senseonics Holdings Inc stock is currently priced at $0.5311, with a 24-hour trading volume of 4.31M.
It has seen a -5.77% decreased in the last 24 hours and a -24.16% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.5618 pivot point. If it approaches the $0.5363 support level, significant changes may occur.
Senseonics Holdings Inc Stock (SENS) Financials Data
Senseonics Holdings Inc (SENS) Revenue 2023
SENS reported a revenue (TTM) of $22.39 million for the quarter ending December 31, 2023, a +36.62% rise year-over-year.
Senseonics Holdings Inc (SENS) Net Income 2023
SENS net income (TTM) was -$60.39 million for the quarter ending December 31, 2023, a -142.49% decrease year-over-year.
Senseonics Holdings Inc (SENS) Cash Flow 2023
SENS recorded a free cash flow (TTM) of -$70.51 million for the quarter ending December 31, 2023, a -5.84% decrease year-over-year.
Senseonics Holdings Inc (SENS) Earnings per Share 2023
SENS earnings per share (TTM) was -$0.1118 for the quarter ending December 31, 2023, a +44.10% growth year-over-year.
Senseonics Holdings Inc Stock (SENS) Latest News
Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga
Hewlett Packard Enterprise Posts Mixed Q1 Results, Joins Fisker, Plug Power And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Benzinga
Senseonics Holdings (SENS) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
Top Penny Stocks To Buy Now? 4 To Watch Under $4
PennyStocks
5 Hot Penny Stocks To Watch Today
PennyStocks
Phreesia (PHR) Surges 10.3%: Is This an Indication of Further Gains?
Zacks Investment Research
About Senseonics Holdings Inc
Senseonics Holdings, Inc., a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days. The company has a research and development license agreement with TypeZero Technologies, Inc. and Roche Diabetes Care, Inc. to develop a closed loop diabetes management system that allow users to automatically maintain tight glucose control while avoiding hypoglycemia. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
Cap:
|
Volume (24h):